- Location
1
result for "
therapies developer
"-
Respicardia Receives Approval to Commence Pivotal Trial of Remedesystem for CSA Patients
May 3, 2013Respicardia, a US-based implantable therapies developer, has received approval from the US Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) to begin the pivotal trial of remedē System. The trial will ...
Tags: Respicardia, therapies developer
